Partnering for pharmaceutical companies

Optimised nebulisers for advanced aerosol therapies

PARI collaborates with pharmaceutical companies to develop and commercialise advanced aerosol therapies. These are based on the optimisation of an efficient aerosol delivery platform, called eFlow Technology, to a drug formulation. Such eFlow Technology nebulisers are tailored to specific medications and the needs of the respective patient population.

PARI has extensive experience in the field of liquid aerosol delivery to the respiratory tract. More than 12 pharmaceutical companies already trust in eFlow Technology nebulisers and PARI´s expertise for the administration of their inhaled medication – from preclinical to commercial. Patients benefit from short nebulisation times, ease-of-use and clinically proven aerosol delivery.

Find out more about our technology, projects, services and success stories!

New Drug-Nebuliser combination Products

Developing new drug-nebuliser combination products

Are you interested in the critical success factors and opportunities for bringing a new vibrating membrane nebuliser for a drug-device combination product to the market?

Read more

Video on PARI´s eFlow Partnering

Watch this video to learn about PARI´s expertise in developing and manufacturing optimised nebulisers – the device part of innovative drug-device combinations for the treatment of respiratory diseases.

Some facts about PARI and its partnering for pharmaceutical companies



At a glance – some facts about PARI and how we are able to contribute to pharma companies´ success with drugs for nebulization.

Download Infographic

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!


I have acknowledged the information regarding data processing.